Abstract
Inosine monophosphate dehydrogenase (IMPDH), an NAD-dependent enzyme that controls de novo synthesis of guanine nucleotides, has received considerable interest in recent years as an important target enzyme, not only for the discovery of anticancer drugs, but also for antiviral, antiparasitic, and immunosuppressive chemotherapy. The field of IMPDH inhibitor research is highly important for providing potential therapeutics against a validated target for disease intervention. This patent review examines the chemical structures and biological activities of recently reported IMPDH inhibitors. Patent databases SciFinder and Espacenet and Delphion were used to locate patent applications that were published between January 2002 and July 2012, claiming chemical structures for use as IMPDH inhibitors. From 2002 to 2012, around 47 primary patent applications have claimed IMPDH inhibitors, which we analyzed by target and applicant. The level of newly published patent applications covering IMPDH inhibitors remains high and a diverse range of scaffolds has been claimed.
Keywords: Anticancer, antiviral, chemotherapy, immunosuppression, IMP-deydrogenase, IMPDH, inhibitor design
Recent Patents on Anti-Cancer Drug Discovery
Title:Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade
Volume: 8 Issue: 2
Author(s): Riccardo Petrelli, Patrizia Vita, Ilaria Torquati, Krzysztof Felczak, Daniel J. Wilson, Palmarisa Franchetti and Loredana Cappellacci
Affiliation:
Keywords: Anticancer, antiviral, chemotherapy, immunosuppression, IMP-deydrogenase, IMPDH, inhibitor design
Abstract: Inosine monophosphate dehydrogenase (IMPDH), an NAD-dependent enzyme that controls de novo synthesis of guanine nucleotides, has received considerable interest in recent years as an important target enzyme, not only for the discovery of anticancer drugs, but also for antiviral, antiparasitic, and immunosuppressive chemotherapy. The field of IMPDH inhibitor research is highly important for providing potential therapeutics against a validated target for disease intervention. This patent review examines the chemical structures and biological activities of recently reported IMPDH inhibitors. Patent databases SciFinder and Espacenet and Delphion were used to locate patent applications that were published between January 2002 and July 2012, claiming chemical structures for use as IMPDH inhibitors. From 2002 to 2012, around 47 primary patent applications have claimed IMPDH inhibitors, which we analyzed by target and applicant. The level of newly published patent applications covering IMPDH inhibitors remains high and a diverse range of scaffolds has been claimed.
Export Options
About this article
Cite this article as:
Petrelli Riccardo, Vita Patrizia, Torquati Ilaria, Felczak Krzysztof, J. Wilson Daniel, Franchetti Palmarisa and Cappellacci Loredana, Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade, Recent Patents on Anti-Cancer Drug Discovery 2013; 8 (2) . https://dx.doi.org/10.2174/1574892811308020001
DOI https://dx.doi.org/10.2174/1574892811308020001 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Ovary Feels Fine when Paracrine and Autocrine Networks Cooperate with Gonadotropins in the Regulation of Folliculogenesis
Current Pharmaceutical Design Neuroprotective Gene Therapy for the Treatment of Inherited Retinal Degeneration
Current Gene Therapy Pharmacogenomics of Non-Small Cell Lung Cancer
Current Pharmacogenomics Understanding XPO1 Target Networks Using Systems Biology and Mathematical Modeling
Current Pharmaceutical Design CDK Inhibitors Induce Mitochondria-mediated Apoptosis Through the Activation of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells
Current Pharmaceutical Design ANTI-ADHESION Evolves To a Promising Therapeutic Concept in Oncology
Current Medicinal Chemistry Perspectives in Biomolecular Therapeutic Intervention in Cancer: From the Early to the New Strategies With Type I Interferons
Current Medicinal Chemistry Leukocyte P2 Receptors: A Novel Target for Anti-inflammatory and Antitumor Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Retinoic Acid Signaling in P19 Stem Cell Differentiation
Anti-Cancer Agents in Medicinal Chemistry Heat Shock Protein 90 Inhibitors as Therapeutic Agents
Recent Patents on Anti-Cancer Drug Discovery Posterior Reversible Encephalopathy Syndrome in Leukemic Children: A Sensitive Issue
Current Drug Safety Involvement of Cannabinoids in Cellular Proliferation
Mini-Reviews in Medicinal Chemistry Nanotechnology, A Tool for Diagnostics and Treatment of Cancer
Current Topics in Medicinal Chemistry Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies
Current Drug Targets Sumoylation Pathway as Potential Therapeutic Targets in Cancer
Current Molecular Medicine Towards a Gene Therapy Clinical Trial for Epidermolysis Bullosa
Reviews on Recent Clinical Trials Natural Antioxidants: Therapeutic Prospects for Cancer and Neurological Diseases
Mini-Reviews in Medicinal Chemistry De Novo Design of New Inhibitor of Mutated Tyrosine-Kinase for the Myeloid Leukemia Treatment
Current Pharmaceutical Design Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) The Transcription Factor ETS-1: Its Role in Tumour Development and Strategies for its Inhibition
Mini-Reviews in Medicinal Chemistry